On November 6, 2023, KRYSTAL BIOTECH ($NASDAQ:KRYS) announced their earnings results for FY2023 Q3, reporting total revenue of USD 8.6 million, a marked improvement from the 0.0 million reported in the same period the previous year. Net income also rose from -29.8 million to USD 80.8 million.
The company’s stock opened at $112.0 but closed at $103.8, representing a 15.0% plunge from the prior closing price of 122.2. This decline was unexpected, as KRYSTAL BIOTECH had been trending upwards in the past few months. The news signals a shift in the market, as investors become increasingly cautious about the company’s ability to maintain its record-breaking performance. Despite this, analysts remain optimistic that KRYSTAL BIOTECH will be able to continue to build on its success and emerge as a leader in the industry.
The company is expected to continue to make investments in research and development to spur further innovation and growth. For now, investors are encouraged to take a wait-and-see approach until more information is released to better assess the situation. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Krystal Biotech. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Krystal Biotech. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Krystal Biotech. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Krystal Biotech are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Krystal Biotech Intrinsic Value Calculation
At GoodWhale, we have conducted an analysis of KRYSTAL BIOTECH‘s financials, using our proprietary Valuation Line to calculate the intrinsic value of KRYSTAL BIOTECH’s share. After our calculations, we believe the intrinsic value of KRYSTAL BIOTECH’s share is around $94.6. However, at the time of writing, KRYSTAL BIOTECH stock is currently traded at $103.8, which is a fair price but slightly overvalued by 9.8%. More…
Star Chart Analysis
The company is among several biopharmaceutical companies in the industry, including GT Biopharma Inc, Jounce Therapeutics Inc, and CytomX Therapeutics Inc, that are focused on developing innovative treatments for serious diseases.
GBT Biopharma Inc is a biopharmaceutical company that develops and commercializes treatments for cancer and other diseases. The company has a market cap of 35.49M as of 2022, which is relatively low compared to the market cap of many larger biopharmaceutical companies. Additionally, the company has a negative Return on Equity (ROE) of -132.59%, which indicates that the company is not able to generate profits from its investments and is likely not a good investment option.
– Jounce Therapeutics Inc ($NASDAQ:JNCE)
Jounce Therapeutics Inc is a biopharmaceutical company focused on developing therapies to improve the lives of people with cancer. The company currently has a market cap of 40.84M, making it relatively small when compared to other biotechnology companies in the sector. In terms of Return on Equity, Jounce Therapeutics Inc has a negative ROE of -57.85%. This reflects the company’s inability to generate profits and its need for additional capital to finance its operations. Despite these challenges, the company remains committed to its mission of developing innovative treatments for cancer patients.
– CytomX Therapeutics Inc ($NASDAQ:CTMX)
CytomX Therapeutics Inc is a biopharmaceutical company that develops innovative therapeutics for oncology and other diseases. The company’s market cap as of 2022 is 102.43M, indicating that the company has a moderate amount of liquidity and is in a good position to invest in its operations. However, its Return on Equity (ROE) of -160.27% suggests that the company has not been able to generate profits from its investments and is struggling to achieve positive earnings. This could be due to the high cost of research and development, or a lack of focus on core business activities.
KRYSTAL BIOTECH has reported strong financial results for FY2023 Q3 with total revenue of USD 8.6 million and net income of USD 80.8 million, both representing a significant year-over-year increase. However, investors reacted negatively to the news and the stock price dropped on the same day. Given these strong financial results, investors should consider taking a closer look at KRYSTAL BIOTECH as a potential investment opportunity. The company has demonstrated strong growth and could continue to see gains in the near future.